<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40892689</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9786</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>Cerebrovascular diseases (Basel, Switzerland)</Title><ISOAbbreviation>Cerebrovasc Dis</ISOAbbreviation></Journal><ArticleTitle>Statistical Analysis Plan for a Randomized Controlled Trial of Intensive Blood Pressure Control on Cardiovascular risk Reduction in Patients with Atrial Fibrillation.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>12</EndPage><MedlinePgn>1-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000548288</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Elevated blood pressure (BP) is a key modifiable risk factor for cardiovascular (CV) complications in patients with atrial fibrillation (AF). While current guidelines recommend modest BP targets, the optimal target in AF patients remains uncertain. The Cardiovascular Risk Reduction in Atrial Fibrillation Trial (CRAFT) is a multicenter, prospective, randomized, open-label, blinded-endpoint trial that evaluates whether intensive home systolic BP control (&lt;120 mmHg) is superior to standard BP control (&lt;135 mmHg) in reducing major CV events. The primary outcome is a hierarchical composite of time to CV death, stroke, myocardial infarction, and heart failure hospitalization. A total sample of 1,675 participants provides 80% power to detect a win ratio of 1.50 between groups after a mean of 3 years of follow-up.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This statistical analysis plan (SAP) was developed by the trial statistician and principal investigators, in collaboration with the steering committee and international experts. The SAP specifies the planned analyses of baseline characteristics, patients' intervention, primary and secondary outcomes, subgroup effects, and safety outcomes. Analyses will be conducted on an intention-to-treat (ITT) analysis using the win-ratio method for the primary endpoint, and Cox proportional hazards and Poisson regression for secondary analyses. Sensitivity analyses and strategies for handling missing data are also described.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">A pre-defined SAP was established for the CRAFT trial to ensure a transparent and verifiable analysis. The SAP was finalized prospectively, independent of treatment assignment, with the goal of preserving internal validity and minimizing analytical bias.</AbstractText><CopyrightInformation>S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Xiaolei</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Chao</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhiyan</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Arima</LastName><ForeName>Hisatomi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xia</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Billot</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Neal</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Rodgers</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hillis</LastName><ForeName>Graham S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Anushka</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Jianzeng</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Craig S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Changsheng</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cerebrovasc Dis</MedlineTA><NlmUniqueID>9100851</NlmUniqueID><ISSNLinking>1015-9770</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Statistical analysis plan</Keyword><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">hypertension blood pressure Trial registration: ClinicalTrials.gov (NCT04347330).</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>22</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>22</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40892689</ArticleId><ArticleId IdType="doi">10.1159/000548288</ArticleId><ArticleId IdType="pii">000548288</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>